{{Rsnum
|rsid=4466137
|Gene=HAPLN1
|Chromosome=5
|position=83689920
|Orientation=plus
|GMAF=0.2121
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=HAPLN1
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 61.9 | 32.7 | 5.3
| HCB | 65.7 | 32.1 | 2.2
| JPT | 73.5 | 24.8 | 1.8
| YRI | 68.7 | 29.3 | 2.0
| ASW | 66.7 | 28.1 | 5.3
| CHB | 65.7 | 32.1 | 2.2
| CHD | 65.1 | 33.9 | 0.9
| GIH | 51.5 | 38.4 | 10.1
| LWK | 75.5 | 21.8 | 2.7
| MEX | 44.8 | 46.6 | 8.6
| MKK | 57.1 | 39.7 | 3.2
| TSI | 58.8 | 34.3 | 6.9
| HapMapRevision=28
}}

{{GWAS Summary
|SNP=rs4466137
|PubMedID=17903305
|Condition=Prostate cancer
|Gene=HAPLN1
|Risk Allele=
|pValue=3.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs4466137
|Name_s=
|Gene_s=HAPLN1
|Feature=
|Evidence=PubMed ID:17903305; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356386
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4466137
|overall_frequency_n=93
|overall_frequency_d=128
|overall_frequency=0.726562
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=83
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}